Alembic gets FDA nod for generic ProAmatine

Press enter to search
Close search
Open Menu

Alembic gets FDA nod for generic ProAmatine

By Sandra Levy - 01/25/2021

Patients with symptomatic orthostatic hypotension can expect to have a new generic treatment.

The Food and Drug Administration has given the green light to Alembic for midodrine hydrochloride tablets, in dosage strengths of 2.5 mg, 5 mg, and 10 mg.

The product is the generic of Takeda’s ProAmatine tablets.

Midodrine hydrochloride tablets have a market value of roughly $60 million for the 12 months ended September 2020, according to IQVIA.

Related Topics